Is Esperion Therapeutics Inc (ESPR) overvalued? · rev $332.3M
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Esperion Therapeutics Inc (ESPR) looks expensive on cached numbers — not a short thesis.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
ESPR currently screens at market cap $816.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ESPR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ESPR stock page for the full model, not this heading.
Not investment advice.